Fundraising FoxFlagship Pioneering — 2018 Investments
3 investments dated 2018 · listed companies and verified rows first · show all
Sana is a biotech company developing engineered cell medicines, including gene therapies for gene modification and delivery, cell replacement therapies using stem cell biology, and manufacturing solutions to improve patient access to these treatments.
BiotechHealthtechMedical DevicesSeattle, US
Richard Mulligan(Director)inHans Bishop(Founder)Steve Harr(Founder)James J. MacDonald(Executive Officer)Nathan Hardy(Executive Officer)
.jpg?itok=YnNGtnt9)
Board seatGeoffrey von Maltzahn· per SEC Form D
Co-investorsAmerican Family VenturesARCH Venture PartnersCatalytic Impact FoundationF-Prime CapitalGV (Google Ventures)Innovating Capital+8 more
BiotechCambridge, US
Jennifer Glennon(Executive Officer)inBalkrishan (Simba) Gill, Ph.D.(Executive Officer, Director)Duncan McHale(Executive Officer)inWilliam DeVaul(Executive Officer)inMark Bodmer, Ph.D.(Executive Officer)
BoardNoubar B. Afeyan, Ph.D.(Director)
Co-investorsGV (Google Ventures)SV Health InvestorsAlexandriaKaiser Permanente VenturesMayo Clinic Ventures
KSQ Therapeutics develops eTIL therapies—engineered tumor-infiltrating lymphocyte treatments for solid tumors—using its proprietary CRISPRomics platform to identify and target novel therapeutic candidates through genome-wide CRISPR/Cas9 functional genomic screens.
AI & Machine LearningBiotechMedical DevicesCambridge, US
Tim Wang(Cofounder)JOHN TRZUPEK, PH.D.(TREASURER, SECRETARY & CHIEF FINANCIAL OFFICER)DAVID P. MEEKER, M.D.(PRESIDENT AND CHIEF EXECUTIVE OFFICER)inFRANK STEGMEIER, PH.D.(CHIEF SCIENTIFIC OFFICER)Qasim Rizvi(Chief Executive Officer)inJAMES GILBERT(Director)
Co-investorsAlpha Wave GlobalARCH Venture PartnersLAVLG Technology VenturesLilly Asia VenturesBaillie Gifford+3 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.